Page 53 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

ASCT
not upfront (7·7% with PR at end-of-treatment PET, 2·2% at time of relapse)
NR
NR
depending on stage and site preplanned,
(R-)CHOP21: (rituximab,) cyclophosphamide, doxorubicin, vincristine, prednisone given with a 3 week interval between cycles. (R-)CHOP14: (rituximab,) cyclophosphamide, doxorubicin, vincristine, prednisone given with a 2 week interval between cycles. authors replied that 29/32 DLBCL/PMCL patients received R-CHOP21 and 3/32 received CHOP21. authors replied that only 1 patient with DLBCL was younger than 18 years old. data of DLBCL/PMBCL patients only (received from authors) number of I-PET scans available for (central) review
only available for complete patient cohort
a
b
c
d
e
f
g
Abbreviations:No=number,RT=radiotherapy,ASCT=autologousstemcelltransplantation,(R-)CHOP=(rituximab,)cyclophosphamide,doxorubicin,vincristine,prednisone, B-cell lymphoma, IQR=interquartile range, MACOP-B= methotrexate, cytarabine, cyclophosphamide, vincristine, prednisone, bleomycin, CNOP=cyclophosphamide, R=rituximab, NR=not reported, SD=standard deviation, IVAC=ifosfamide, mesna, cytarabine, etoposide, IFRT= involved field radiotherapy, PMBCL=primary mediastinal international prognostic index, excl. crit=exclusion criterium, VNCOP-B= etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisone, bleomycin, PR=partial mitoxantrone, vincristine, prednisone, HCVAD= hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone, CHOEP= cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone, R-ACVBP= rituximab, doxorubicin, vindesine, bleomycin, prednisone, pts=patients, HDT=high dose therapy, aaIPI=age adjusted response, CVP=cyclophosphamide, vincristine, prednisone, DHAP= dexamethasone, cytarabine, cisplatin, MTX-AraC= methotrexate, cytarabine.
Predictive value of interim PET in DLBCL
RT
Male
Table 1 Continued
a a Treatment characteristics First-line treatment 16·7% R-VNCOP-B 83·3% R-CHOP21 92·3% R-MACOP-B 7·7% R-CHOP21 DLBCL: (>=60yr) (<60yr) PMBCL: 67·0% Stage III-IV DLBCL/ 57 (12 -85) 60·7% 75·4% 90.6% R-CHOP21 52·7% efcccg Age median 54 (17-90) (range) DLBCL DLBCL: PMBCL: (2007) /61 PMBCL 9.4% CHOP21 85·7% 14·3% Patient characteristics patients No. of 32
91 retrospective retrospective
design
Study
Study characteristics
53 g First author,
Zinzani et al
52
Zhao et al
year
(2011)
51
3